Opus Genetics Inc IRD.OQ IRD.O is expected to show a fall in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The Durham North Carolina-based company is expected to report a 20.5% decrease in revenue to $3.075 million from $3.87 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Opus Genetics Inc is for a loss of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Opus Genetics Inc is $8.00, about 74.6% above its last closing price of $2.03
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.21 | -0.20 | -0.12 | Beat | 41.5 |
Mar. 31 2025 | -0.26 | -0.25 | -0.24 | Beat | 4 |
Dec. 31 2024 | -0.26 | -0.22 | Beat | 14.3 | |
Sep. 30 2024 | -0.25 | -0.24 | -0.29 | Missed | -22.1 |
Jun. 30 2024 | -0.28 | -0.25 | -0.30 | Missed | -17.6 |
Mar. 31 2024 | -0.11 | -0.13 | -0.29 | Missed | -116.4 |
Dec. 31 2023 | -0.03 | -0.05 | -0.21 | Missed | -300 |
Sep. 30 2023 | -0.24 | -0.22 | 0.25 | Beat | 212.6 |
This summary was machine generated November 7 at 15:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments